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With this presentation, my role is to help to stir the discussion. Perhaps it will open the 
dialogue so that we have a sense of where we have been, where we are, and then what’s 
ahead. Figure  shows a photograph from 986, and in Figure  is a photograph taken 
two years later. We developed a tomato phenotype—viral coat-protein-mediated resistance 
to a common disease of tomato—with a technology that we hoped would be applicable 
to other horticultural and agricultural crops. 
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Figure . 985: Coat-protein-mediated resistance to virus infection in tomato.
Since the field trial, fewer than six public-sector transgenic crops have reached the 
market in the United States. For the last 5 or 8 years, we’ve asked why it’s been that 
way and if the situation will improve in the near future. If it does get better, what steps 
will be required to get there. I will discuss this in the context of reduction of the use of 
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pesticides and improved sustainability, and the role that this and other sciences play in 
the economy.
Increasingly, the topic of this conference, biotechnology and horticultural crops, is 
about the ability of producers to make a profit, and how future agriculture, globally, will 
include specialty crops. Although we cannot accurately predict the future of technical 
successes or consumer acceptance of new crop varieties, we should be planning ahead, 
as it can take 0 or more years to bring a new technology to the market. We should be 
looking ahead at what the economic picture may be—knowing what farming is like today, 
knowing what smallholders in Africa might want, or what might be useful in the prairies 
of western Canada, in Florida and other regions of the world. 
I want to consider the technical opportunities and market challenges and possible 
solutions in the biotechnology of specialty crops, and then look for trends and goals that 
may portend a brighter future. We know where we’ve been. The technologies that were 
developed in the 980s in transgenesis provided good products that brought value to 
producers and, arguably, to consumers by keeping food available at reasonable cost; also, 
they brought environmental benefits. 
However, progress in applying the new technologies to specialty crops has been lim-
ited. The stumbling blocks are not technical, but regulatory and social. The challenges 
are magnified by the fact that the crops are of relatively small acreage and that consumer 
concerns over genetically modified (GM) crops are not waning. Activists are becoming 
more vocal, and we don’t seem to have a plan for mitigation of damage that they cause 
to the effort to develop useful varieties through biotechnology. Nevertheless, public-sec-
tor scientists have continued their investment in the technology as it fits their research 
goals, and they continue to create products that are likely to have value, should they be 
adopted. As a plant pathologist, it is heartening to see the progress that has been made 
by researchers in the public sector, for example improving resistance to fungi, bacteria, 
Figure . 987: First field trial of genetically modified tomato plants similar to those 
described in Figure , conducted in Jerseyville, Illinois.
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insects and parasites, including parasitic nematodes, in specialty crops. Virus-resistant 
traits have been introduced in many specialty crops. 
Biotechnology has also been employed to enhance nutrient content in tomato, rice, 
maize and other crops. Good examples are the purple tomato with high levels of carot-
enoids, increased tolerance of disease and strong post-harvest stability, vitamin-C-rich 
carrot, and potato varieties resistant to early blight and to late blight. A large number of 
virus-resistant crops have been developed by researchers abroad, showing how science 
and biotechnology have proven to be valuable. The question is, Will the full potential for 
application to specialty crops be realized? Given all of the good work that has been done, 
what’s stopping it? Why isn’t it moving forward? It is not a technical problem. Clearly, 
other issues need to be addressed.
A Long-Term View is Necessary
Let’s look at today’s problems in the context of what the long-term future might bring in 
agriculture, and ask several questions for US agriculture:
• Who is defining the long-term future of US agriculture in competition with 
BRIC1 nations and other emerging economies, and how will decisions in technol-
ogy and markets impact the future? 
 — What will be the impact on US agriculture of increased productivity of 
 commodity crops in Eastern Europe and South America?
 — Over what timeframe will changes occur?
• In the context of: increasing focus on health and nutrition, how will technology 
in horticultural crops be judged? How will value added to agricultural products 
be captured and will it change? What will be the impact of ongoing changes, both 
positive and negative, on farm economies in an era of high land values? And how 
will land values’ impact on the roles of specialty versus commodity crops in the 
US economy change?
• What will be the markets for US agriculture exports when African nations 
 become food self-sufficient in 0 or 5 years (as some have predicted), and 
when/if Eastern Europe produces more wheat and corn for European markets, 
and when Brazil fully exploits the Cerrado2 for production of increasing amounts 
of soybean and corn?
If you ask who is in charge of outlining a plan for America’s agricultural future, you 
may not find a long-term plan, though a mid-term roadmap was developed by the USDA 
in 0. A useful roadmap should identify and address the challenges to the future of 
America’s agriculture. Are increases in yields possible in commodity agriculture and what 
is required to achieve yield goals? What will impact the future profitability of specialty 
crops and how will challenges be managed? At the end of the day, a major issue is whether 
1Brazil, Russia, India and China.
2A vast tropical savanna, the largest of Brazil’s major habitat types after Amazonia.
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or not the farmer/producer can make a living, whether (s)he can still pay the mortgage 
on the land and purchase the equipment that will affect profitability, and contribute to 
the wellbeing of the family. A useful roadmap will plan forward to provide a basis for 
ongoing success in the industry.
In a recent publication—Agricultural Innovation: The United States in a Changing 
Global Reality—Philip Pardey and Jason Beddow (03) enumerated future challenges to 
agricultural economics that can be useful. We in the sciences and business sector, focused 
as we are on our own projects and products, often forget the bigger picture, to our detri-
ment. To capture new value from agricultural products, there’s an increasing awareness 
of the potential value of a growing bioeconomy and of biorefineries. Similarly, the grow-
ing role of consumer preferences and demands for agro-sustainability will continue to 
change agriculture. For example, I am convinced that biotechnology can reduce the use 
of agrichemicals on fruits and vegetables, improve quality and yields, reduce post-harvest 
losses, enhance climate resilience, and increase nutrient value and economic returns. If I 
am correct, investments made in research that helps to achieve these goals will prove to 
be warranted. The risk is that I am incorrect and that consumers will not push to reduce 
agrichemicals. To increase the likelihood that sound research goals are set, it will be help-
ful to engage the broad range of skills from the social sciences—including economics, 
consumer studies and policymaking—in the goal-setting process.
The Right Technologies at the Right Time
Recent advances in the science and technology of molecular plant breeding make it pos-
sible to consider the future of applications of biotechnology to horticultural and specialty 
crops that may be brought forward, for example new energy crops and those that produce 
biopolymers for the rubber and plastics industries. Quality of product and quantity of 
production can now be advanced rapidly by modern breeding and used to improve re-
silience to climate change and extreme weather, and to increase fertilizer-use efficiency. 
Furthermore, previously unexploited specialty crops may be employed for new industrial 
uses by applications of synthetic biology to alter metabolism and create useful products. 
Tools available today are far more powerful and useful than what we used, or imagined, 
in 985 when we developed the first virus-resistant tomato plants. New tools include:
• High-frequency mutagenesis to create variability and select desired changes in 
target gene(s)
• Directed nucleotide changes in target genes to recapitulate known/desired varia-
tions
• Site-specific gene insertion
• Artificial chromosomes to carry multiple genes
• Deletion/inactivation of non-desired gene(s) via meganucleases
• Non-transgenic progeny via segregation in breeding
• Gene inactivation by RNAi-based approaches, including directed methylation 
and knockout.
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We can expect continued technical improvements of course, and some of the new 
technologies will push the relevant regulatory processes to consider advantages of enabling 
technologies as well as the products to which they lead. The objective of the new tech-
nologies is not to circumvent regulatory oversight, but to develop new materials that will 
have increased value for those who take them to the marketplace and to the consumers 
who will use them.
Opportunities as Patents Expire
New opportunities for development will come through the expiration of patents and will 
lead the way to generic products, or will release constraints on commercial development of 
new products. Although patent protection for Agrobacterium-mediated transformation of 
plants will not expire until the late 00s, products that made use of the technology will 
become generic much sooner. For example, the coat-protein gene-based virus-resistance 
patent was issued (7 years after filing) in 003, and will be generic by 00.
Certain technologies for Roundup resistance, and for insect resistance will likewise 
expire in the early 00s and lead to new opportunities for new applications.
Challenges and Threats
The key challenges to development of biotechnology products in specialty and horticul-
tural crops remain around the cost of regulation of traits and in accessing technologies 
resulting from industry investments in first-generation GM crops. We look forward to 
having not only resistances to disease and insects that were developed in first-generation 
crops, but also we look forward to herbicide tolerance and other traits that will come 
off-patent in the next 5 to 0 years.
Many relevant and valuable traits have been demonstrated in specialty crops, but few 
have been introduced in the marketplace. As others have reported, the significant cost 
of deregulating a biotechnology product compared with the value of the trait per se is a 
real and ongoing problem, especially in those cases when a disease or insect pest affects 
a relatively small geographical area. 
In other cases, there is lack of scientific and technical information to bring to bear on 
a problem. A significant challenge in North America—as relevant in Canada as in the 
United States—is reduced investment in discovery research. We all ought to be concerned 
about this. Pardey and Beddow (03) noted that increases in investment in agricultural 
science in the BRIC nations is directly related to increases in their crop productivity. 
In contrast, in North America there is flattened or reduced investment in research in 
agriculture-related sciences in inflation-adjusted terms; we are not keeping up with our 
competitors, although we have built successful agriculture economies on such competition. 
In 0, the United States exported nearly $40 billion worth of agricultural products. 
Yet, in the United States, the Department of Agriculture invests less than $.5 billion 
dollars annually in research, and less than $350 million dollars is available for competitive 
research grants. That level of investment is catching up with us, begging the question of 
agricultural profitability in the continent in 0 to 50 years. The negative impact of less 
discovery research could be substantial.
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The weak history of innovation and entrepreneurship in our public institutions, upon 
which to build new enterprises and refresh established products, has led to a weak pipeline 
of new technologies. I participate as an advisor on several venture-capital funds and the 
paucity of innovation has, to date, been noticeable and is significantly less dynamic than 
from the biomedical community, and far less than for the IT sector.
It’s not that the science itself is not outstanding. It is common to hear venture-fund 
managers reflect on the lack of innovation in this market sector and to relate it to the fact 
that the way to market for products improved by certain genetic technologies is unclear. 
The weak pipeline of new technologies, and the heavy and high-cost regulatory process in 
the United States and globally causes delays in release of new products. This is confounded 
by the lack of harmonized and synchronous approval processes that have together slowed 
product approval, which, in turn, has slowed innovation. This is further exacerbated by the 
weak acceptance of new products by a very vocal minority of consumers—in particular 
products developed by multinational corporations—which affects all of us.
These are some of the significant threats and challenges that affect the applications of 
biotechnology to horticultural and specialty corps. On the upside, the USDA process 
has improved modestly. There are additional requirements, but maybe we should have 
predicted some of the changes, for example the growing need for studies of environmental 
impact of new products, as unscientific as it may seem in some cases. Maybe we should 
have expected the changes. EPA and the NEPA3 rules continue to represent substantial 
barriers to the release of new products.
The global approval process—which negatively impacts release of new products here 
in the United States—continues to be slowed by a variety of factors. And then there are 
events like the GM wheat that appeared recently in Oregon, and you wonder how long 
that tale will last, and how it will be used and by which group. Careful investigation is 
needed to elucidate how that happened in order to prevent recurrence, whether by ac-
cident or by intention.
Consumer concerns around GM crops are no lower than they were a decade ago, 
and are growing in some regions, as indicated by the labeling initiatives that we see in as 
many as 0 states. The same issues apply in Canada and in countries around the globe: 
we as scientists have a lot of work ahead as we take a more active role in discussions about 
GM foods.
Deregulation of Proven Technologies
Many scientists, though not all, are convinced that some of the controversies around 
GM food would diminish () if the benefits of GM varieties were more apparent to the 
consumer, and () if regulatory hurdles were reduced to levels commensurate with risk. 
It would help if agencies would deregulate based on past experience with a technology, 
and based on scientific evidence of no or minimum risk. At the same time, this would 
demonstrate to the public that—while the regulators are watching carefully—this is not 
3National Environmental Policy Act.
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a dangerous technology. We have boxed ourselves in vis-à-vis consumers by saying that 
the technology needs lots of regulation, when, in fact, most in the science community 
recognizes that it does not. Many feel that it is logical to deregulate Agrobacterium-mediated 
transformation, at least some Bt genes, and genes that confer resistance to herbicides 
proven to be effective and safe for the environment. Similarly, pathogen-derived resis-
tance to viruses should be deregulated. Also, I would include all RNAi approaches to 
control pathogens, in particular when siRNAs are shown to be part of an innate defense 
mechanism. However, I am not optimistic that this will happen in the near future. But, 
since we have 0 to 5 years of success with some technologies, we ought to be pushing 
APHIS and EPA to deregulate certain technologies more actively than we are. And if 
APHIS is, as they claim, a science-based regulatory agency, we should expect to receive 
informed responses. This may be a way that we in the academic community could help 
to move beyond the current slow-and-go regulatory process and move new products to 
market more rapidly than they are today.
Perception of Multinational Companies
I am convinced that many of the challenges that we in the public sector face in our 
 difficulties in GM agriculture are because many of us in university research are not seen 
as relevant to local agriculture per se. It is not easy for consumers of food to connect with 
our laboratory research. Instead, they generally see agriculture and the food economy as 
connected to large agribusiness and multinational food companies, which, they are con-
vinced, do not have consumers’ interests at heart. Although we know that not to be the 
case, we academics are either not seen as relevant or are painted with the same brush.
For some time, I have had a sense that this issue has arisen because our universities are 
now less involved in product development than historically. One way to minimize the 
latter may be for regulatory agencies to deregulate essential technologies that are broadly 
applicable, so that we can use them to address local problems. Horticultural and specialty 
crops are regional in their relevance. In the mid-990s, Benigno Villalón who developed 
thousands of varieties of hot chili peppers in Texas, sent a postdoc to my lab to develop 
coat-protein resistance to viruses, which commonly infect chili peppers. However, he 
withdrew the effort on realizing what would be involved in achieving deregulation. 
Similarly, there is much innate interest in using genetic engineering to tackle local pest 
and disease problems in many crops.
Achieving Deregulation
New technologies are developed in public research institutions as well as in small and large 
privately held companies. The deregulation process as it currently stands is poorly defined 
and costly. Achieving deregulation of virus-resistant papaya, led by Dennis Gonsalves4 
of the USDA in Hawaii is estimated to have cost less than $ million. In Brazil, a new 
virus-resistant Phaseolus bean cost $3.5 million from the start of the project to product 
4Pages 37–46.
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delivery. On the other hand, putting a new trait into a globally important crop—maize, 
soybean or cotton—is expensive, estimated to be between $50 million and $50 mil-
lion, depending upon what is required. This discourages innovation, and it certainly 
discourages venture capitalists from investing in projects to which they cannot predict 
an end-point. In some ways we don’t have a discovery problem in certain technologies, 
but we do have an innovation and translation problem. Policymakers are reluctant to 
develop long-term policies for the agriculture/food sector, including regulatory policies 
for new technologies.
An additional problem is limited understanding of how to achieve customer acceptance 
of biotechnology, due to concerns over food and environmental safety and intellectual 
property rights. The past 0 years haven’t worked well for us, yet we have little concept of 
what we should be doing. A better way forward is not likely to come from multinational 
companies due to lack of trust on the part of consumers. But unless we face this impasse 
and find a better way, in 0 years we will still be asking ourselves, “Why isn’t there more 
acceptance of crops developed with new genetic technologies?”
Messaging Agbiotech for Public Consumption
In 0, Graham Brookes and Peter Barfoot published a paper titled GM Crops: Global 
Socio-Economic and Environmental Impacts 1996–2009, which focused on positive 
 economic impacts, and production and environmental effects of GM crops. Within a 
week of the publication of Brookes and Barfoot (0), Vandana Shiva and colleagues 
(0) published The GMO Emperor Has No Clothes: A Global Citizens [sic] Report on 
the State of GMOs—False Promises, Failed Technologies (Figure 3). Certainly this was no 
coincidence. 
At an NABC conference some years ago, I remember standing and asking her, fol-
lowing her remarks to the attendees, “Do you really teach this to your students? Do you 
call yourself a scientist? Do you really believe what you are saying?” My questions didn’t 
matter, of course. Vandana Shiva has been saying the same things, making the same ac-
cusations, for the last 5 years, and because this is the kind of “stuff” that garners publicity, 
the issue won’t go away. The private sector has yet to learn how to message agriculture 
and biotechnology for public consumption and how to address those who attack their 
work unrelentingly. 
What might be done to counter? In my opinion, we should encourage transparency at 
all stages of the process—from research to testing, to product development and regulatory 
approval. Perhaps we should “open all the books”; perhaps that would help. And, there 
should be more public-sector voices in support of science and technologies in food and 
agriculture. And, in terms of transparency in our work, we need to  demonstrate that we 
are, in fact, looking at real advantages, real sustainability, with real reductions in the use of 
agrochemicals, and other important outcomes for the research that we are engaged in.
Meeting Global Food Security.
What we do in specialty crops is part of the challenge of meeting global food and nutrition 
security. According to the FAO, we must feed another  billion people with sufficient 
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calories and nutrition, from a safe food supply, at acceptable cost, from the same area 
(perhaps up to 0% more) of arable land. This will have to be achieved with less water, 
and smaller inputs of fertilizer and other chemicals. Again according to the FAO, the 
foreseeable future will require a 70% increase in food production, a 43% increase in grain 
production, and a 75% increase in meat production. Specialty crops are part of the solu-
tion, in terms of producer economics as well as part of the solution in nutrition, health, 
and wellbeing of the consumer.
If what we are doing really does matter, the question is: can we broaden the use of 
advanced science and technologies to include horticultural and specialty crops?
Figure 3. 0 report by Vandana Shiva et al.
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